An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated …
Investors have grown a bit snobbish, insisting on buying the highest quality and willing to pay up lavishly to own and flaunt the best. Among the most broadly played investment …
Game-changing anti-obesity medications have posed nothing short of an existential crisis for Weight Watchers parent WW International since they arrived on the scene, but CEO Sima Sistani has been confronting …